3 ASX 200 buy-the-dip opportunities recommended by brokers today

Here are three ASX 200 shares that brokers say are buys following share price tumbles or stagnation in 2023.

Who doesn't love a great ASX 200 buy-the-dip opportunity?

As 2023 draws to a close and we all take a look at the performance of our portfolios this year, is it time to consider buying some new stocks for extra diversification?

And which ASX 200 shares are ripe for investment after languishing or being oversold in 2023?

Well, some top brokers are going to help us out with this question.

Here are three ASX 200 shares that brokers say are buys following share price tumbles or stagnation in 2023.

Woman flexes muscles after donating blood.

Image source: Getty Images

50% upside possible on Qantas shares

The Qantas Airways Limited (ASX: QAN) share price is down 9.3% in the year to date compared to a 9.4% uplift in the ASX 200. It is currently trading at $5.39, up 0.65% on Thursday.

As the chart below shows, Qantas shares remain in a pronounced dip.

The stock's 52-week high is $6.94 and its 52-week low is $4.67.

Qantas has faced a mountain of challenges this year that have damaged its reputation. Customers have vented fury over poor service, cancelled flights, lost baggage and the expiration of COVID-19 credits amid retiring CEO Alan Joyce receiving $21.4 million in earnings over FY23.

There was also a class action lawsuit regarding the handling of cancelled flights during the pandemic. The Federal Court ruled the airline had illegally sacked 1,683 workers, and the Australian Competition and Consumer Commission (ACCC) is suing Qantas for allegedly selling tickets for cancelled flights.

Goldman Sachs has a conviction buy rating on the beleaguered ASX 200 travel share. The broker's 12-month share price target is $8.25, indicating a potential upside of 53% for investors who buy today.

ResMed shares rebounding but there's still time to buy

The ResMed CDI (ASX: RMD) share price is down 17.1% in the year to date. It is currently trading at $25.23, down 0.86% on Thursday.

There has been some recovery in the ResMed share price recently, but it is still well down on its 52-week high of $36.37. The 52-week low is $21.14.

This year's sell-off is largely related to market jitters over the impact of the wonder weight-loss drug, Ozempic.

Originally a diabetes medication, Ozempic is now also being prescribed for obesity, and investors are concerned this may reduce demand for ResMed's sleep apnea devices given obesity is a common precursor to sleep apnea.

Macquarie has an outperform rating on ResMed shares with a $33.40 price target. This implies a potential 32.4% upside for investors who buy now.

Stagnated ASX 200 blue-chip giant a buy right now

The CSL Limited (ASX: CSL) share price has risen by just 1.5% in the year to date. It is currently trading at $286.11, up 0.16% on Thursday.

Its 52-week high is $314.28 and its 52-week low is $228.65.

The healthcare giant has also been affected by Ozempic, given recent studies show it may also be an effective treatment for chronic kidney disease (CKD).

Two years ago, CSL forked out $18 billion to acquire CKD business, Vifor.

Morgan Stanley analyst Sean Laaman also attributes CSL's lacklustre share price performance in 2023 to other product disruption threats and a slower recovery in its plasma collections following COVID-19.

The best time to buy would have been late October when the stock was in the $230 range. However several top brokers say CSL shares are still attractive at today's price level.

Goldman Sachs has a buy rating and a 12-month price target of $309. Citi also has a buy rating and a more bullish $325 price target, implying a potential 13.6% uplift for investors in 2024.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has positions in CSL and Macquarie Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, Macquarie Group, and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »

Smiling woman taking a video through a plane window with her phone.
Broker Notes

Qantas or Virgin shares. Which ASX airline has more upside?

Will either share take off soon?

Read more »

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »